-
MMP-2 Responsive Liposomes for Sequential Immunotherapy
2026-09-10
The reference study developed an MMP-2-responsive, dual-targeting liposome that sequentially delivers the PD-1 pathway blockade peptide AUNP-12 and the IDO inhibitor NLG919 in breast cancer models. Its main contribution is the use of tumor-associated protease activity to coordinate target-cell engagement, peptide release, secondary targeting, and immunosuppressive microenvironment remodeling.
-
gamma-Glu-Cys: From Substrate to Systems Insight
2026-09-09
Discover how gamma-Glu-Cys (γ-Glu-Cys) can function as more than a glutathione precursor: it is a controlled variable for enzyme assays, microbial peptide studies, and plant stress adaptation research. This guide connects molecular design, assay interpretation, and findings from recent Bacillus γ-glutamyl peptide research.
-
E. coli Uracil-DNA Glycosylase (UDG) Guide
2026-09-09
E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil residues from single- and double-stranded DNA to help control uracil-containing PCR carryover. It is intended for DNA workflows only and should not be used with RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.
-
METTL16–SENP3–LTF Drives HCC Ferroptosis Resistance
2026-09-08
Wang et al. identify a METTL16–SENP3–LTF axis that links m6A RNA regulation to iron handling and ferroptosis resistance in hepatocellular carcinoma. The study integrates cellular, organoid, mouse-model, molecular, and clinical analyses, establishing labile iron control as a mechanistic connection between epitranscriptomic regulation and tumor progression.
-
2',7'-Dichlorofluorescein diacetate for ROS Assays
2026-09-08
Build more reliable intracellular ROS measurement workflows with a cell-permeable, fluorogenic redox probe that translates oxidative activity into green fluorescence. This guide connects practical assay design with the ROS-responsive nanocarrier strategy reported for orthotopic pancreatic cancer, while emphasizing controls, normalization, and interpretation limits.
-
(Z)-4-Hydroxytamoxifen in Relapse Research
2026-09-07
A translational perspective on how (Z)-4-Hydroxytamoxifen can sharpen estrogen receptor studies while complementary proliferation-tracing models reveal the dormant ecosystems that drive breast cancer relapse.
-
4μ8C Workflows for ER Stress Mechanism Studies
2026-09-05
Use 4μ8C to isolate IRE1α RNase signaling from broader ER-stress effects in hypoxia, cancer research, and nucleus pulposus cell assays. This workflow pairs branch-selective perturbation with PERK–JAK1–STAT3 readouts, helping distinguish pathway engagement from changes in viability or pyroptosis.
-
Heat-Not-Burn Product Genotoxicity: Key Evidence
2026-09-05
The 2024 reference study compared a heat-not-burn product with conventional cigarettes using complementary rat and cell-based toxicology assays. Its findings indicate lower cytotoxicity and genotoxicity for the tested heat-not-burn product under the experimental conditions, while also showing why multiple endpoints are needed before making broader safety claims.
-
Cell Cycle Assay Kit: Practical Flow Cytometry Guide
2026-09-04
Map DNA-content changes, distinguish cell cycle arrest from apoptotic loss, and build a reproducible flow cytometry workflow with PI and RNase A. The approach is especially useful for cancer research cell proliferation studies, including mechanistic follow-up of epigenetic therapies in leukemia models.
-
Acetylcholine Chloride for Causal Circuit Assays
2026-09-04
Acetylcholine Chloride can do more than reproduce cholinergic responses: it can help researchers separate receptor-level effects from gut–vagus–brain circuit causality. This article presents an assay-design framework grounded in recent Bacteroides fragilis epilepsy research.
-
Hydroxytyrosol in Nicotine-Driven CKD Research
2026-09-03
Hydroxytyrosol offers a focused way to investigate oxidative stress modulation in nicotine-associated kidney injury. This guide translates receptor biology and renal redox mechanisms into rigorous assay design for cardiovascular and inflammation research.
-
Oltipraz Workflows for MASLD Nrf2 Research
2026-09-03
Oltipraz provides a defined small-molecule route to study Nrf2-driven phase II defense alongside lipid injury, autophagy, and ferroptosis readouts. This workflow translates recent MASLD findings into reproducible cell, tissue, and comparative intervention experiments while separating validated observations from practical assay extensions.
-
HotStart 2X Green qPCR Master Mix for Barrier Biology
2026-09-02
HotStart 2X Green qPCR Master Mix supports rigorous SYBR Green qPCR master mix workflows for host–pathogen barrier studies. This guide connects assay chemistry with the TIMP1–GRA24–p38 MAPK findings in Toxoplasma research, emphasizing causal controls, interpretation, and RNA-seq validation.
-
Sulfo-NHS-SS-Biotin for Surface Proteomics
2026-09-02
Sulfo-NHS-SS-Biotin combines water-compatible amine labeling with a DTT-cleavable disulfide linker, making it useful for reversible cell-surface capture and protein purification. Its workflow helps distinguish receptor trafficking defects from total protein loss in proteostasis studies.
-
HNF4A-AS1 Loss Drives Sorafenib Resistance in HCC
2026-09-01
The 2024 Theranostics study identifies liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib-induced ferroptosis in hepatocellular carcinoma. Its loss increases DECR1 expression, depletes intracellular polyunsaturated fatty acids, and supports drug resistance through an METTL3–m6A–YTHDF3 regulatory axis.